PT  - JOURNAL ARTICLE
AU  - Yeoh, Su-Ann
AU  - Gianfrancesco, Milena
AU  - Lawson-Tovey, Saskia
AU  - Hyrich, Kimme L
AU  - Strangfeld, Anja
AU  - Gossec, Laure
AU  - Carmona, Loreto
AU  - Mateus, Elsa F
AU  - Schäfer, Martin
AU  - Richez, Christophe
AU  - Hachulla, Eric
AU  - Holmqvist, Marie
AU  - Scirè, Carlo Alberto
AU  - Lorenz, Hanns-Martin
AU  - Voll, Reinhard E
AU  - Hasseli, Rebecca
AU  - Jayatilleke, Arundathi
AU  - Hsu, Tiffany Y-T
AU  - D’Silva, Kristin M
AU  - Pimentel-Quiroz, Victor R
AU  - Vasquez del Mercado, Monica
AU  - Shinjo, Samuel Katsuyuki
AU  - Neto, Edgard Torres dos Reis
AU  - Junior, Laurindo Ferreira da Rocha
AU  - de Oliveira e Silva Montandon, Ana Carolina
AU  - Pons-Estel, Guillermo J
AU  - Ornella, Sofía
AU  - D'Angelo Exeni, Maria Eugenia
AU  - Velozo, Edson
AU  - Jordan, Paula
AU  - Sirotich, Emily
AU  - Hausmann, Jonathan S
AU  - Liew, Jean W
AU  - Jacobsohn, Lindsay
AU  - Gore-Massy, Monique
AU  - Sufka, Paul
AU  - Grainger, Rebecca
AU  - Bhana, Suleman
AU  - Wallace, Zachary
AU  - Robinson, Philip C
AU  - Yazdany, Jinoos
AU  - Machado, Pedro M
ED  - ,
TI  - Factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy: results from the COVID-19 Global Rheumatology Alliance physician-reported registry
AID  - 10.1136/rmdopen-2022-002508
DP  - 2022 Sep 01
TA  - RMD Open
PG  - e002508
VI  - 8
IP  - 2
4099  - http://rmdopen.bmj.com/content/8/2/e002508.short
4100  - http://rmdopen.bmj.com/content/8/2/e002508.full
SO  - RMD Open2022 Sep 01; 8
AB  - Objectives To investigate factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy (IIM).Methods Demographic data, clinical characteristics and COVID-19 outcome severity of adults with IIM were obtained from the COVID-19 Global Rheumatology Alliance physician-reported registry. A 3-point ordinal COVID-19 severity scale was defined: (1) no hospitalisation, (2) hospitalisation (and no death) and (3) death. ORs were estimated using multivariable ordinal logistic regression. Sensitivity analyses were performed using a 4-point ordinal scale: (1) no hospitalisation, (2) hospitalisation with no oxygen (and no death), (3) hospitalisation with oxygen/ventilation (and no death) and 4) death.Results Of 348 patients, 48% were not hospitalised, 39% were hospitalised (and did not die) and 13% died. Older age (OR=1.59/decade, 95% CI 1.31 to 1.91), high disease activity (OR=3.50, 95% CI 1.25 to 9.83; vs remission), ≥2 comorbidities (OR=2.63, 95% CI 1.39 to 4.98; vs none), prednisolone-equivalent dose >7.5 mg/day (OR=2.40, 95% CI 1.09 to 5.28; vs no intake) and exposure to rituximab (OR=2.71, 95% CI 1.28 to 5.72; vs conventional synthetic disease-modifying antirheumatic drugs only) were independently associated with severe COVID-19. In addition to these variables, in the sensitivity analyses, male sex (OR range: 1.65–1.83; vs female) was also significantly associated with severe outcomes, while COVID-19 diagnosis after 1 October 2020 (OR range: 0.51–0.59; vs on/before 15 June 2020) was significantly associated with less severe outcomes, but these associations were not significant in the main model (OR=1.57, 95% CI 0.95 to 2.59; and OR=0.61, 95% CI 0.37 to 1.00; respectively).Conclusions This is the first large registry data on outcomes of COVID-19 in people with IIM. Older age, male sex, higher comorbidity burden, high disease activity, prednisolone-equivalent dose >7.5 mg/day and rituximab exposure were associated with severe COVID-19. These findings will enable risk stratification and inform management decisions for patients with IIM.Data are available on reasonable request. Applications to access the data should be made to the COVID-19 Global Rheumatology Alliance Steering Committee.